Inhaled Bevacizumab: A case study for delivery to the lung

Bevacizumab is a monoclonal antibody VEGF-inhibitor approved for treatment of cancers, including lung and colon. The goal of this study was to perform a real-time stability study of spray-dried bevacizumab dry powder formulation out to 24 months. 

Download the poster, presented at RDD Europe 2023, to learn more.

You may also be interested in:
Inhalation
Oral Drug Products
Spray Dried Dispersions
Author(s):
Kimberly Shepard, Ph.D.
Director, Respiratory Delivery
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
Technical/Service brief
Room to Grow: Exploring the Capabilities of 15,000L Microbial Manufacturing
Scaling microbial processes requires more than capacity - it demands precision, flexibility, and...
Technical/Service brief
Rapid Cocoon® CAR-T: rapid manufacturing of CAR-T cells with integrated selection in the Cocoon®...
Integrated magnetic separation capabilities enrich for a pure T cell input To enable rapid...
DPS
White paper
Industry-backed, data-driven approaches to enhancing container closure integrity
Container closure integrity (CCI) is central to ensuring product quality and patient...
tech operating dryer
Webinar (on-demand)
Dry powder for intranasal delivery
This webinar is your chance to get ahead in the world of drug delivery. We're...
Presentation (on-demand)
Overcoming biotherapeutic protein expression challenges with advanced vector technology for a range...
The development of biotherapeutic products is complex and the growing prevalence of next-generation...
Webinar (on-demand)
Industrialization of AAV manufacturing with Xcite® transient and stable production platforms
In this presentation, industry experts Suparna Sanyal and Peng Wang from Lonza take you deep into...
Lonza_Bend_EarlyPhaseLab33
Article
Streamlining early phase drug development with continuous flow technologies
As small molecule complexity increases, early-stage development faces new challenges that demand...
Poster
Designing a Plug-and-Play System to Produce Engineered Extracellular Vesicles
Extracellular vesicles (EVs), including exosomes, are being studied extensively and have emerged as...
Poster
Plasmid Engineering and Process Development to Improve Self-Complementary AAV Productivity
Self-complementary AAV (scAAV) vectors were developed by mutating one of the ITRs to form...
Poster
Development of high-performing stable producer cell lines for therapeutic AAV vector manufacturing
Attributed to their safety profiles and transduction efficiencies, recombinant Adeno-associated...
Poster
Adeno-associated virus characterization using nanopore long read sequencing and analysis
Recombinant adeno-associated virus (rAAV) has become a leading vector for in vivo gene delivery. The...
Poster
Large-Scale High Titer Lentiviral Production Using Lonza's Suspension Transient Transfection...
Lentivirus vector (LVV) is a major player in cell and gene therapies. It efficiently transduces both...